Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Minerva Urologica e Nefrologica 2018 October;70(5) > Minerva Urologica e Nefrologica 2018 October;70(5):501-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Urologica e Nefrologica 2018 October;70(5):501-8

DOI: 10.23736/S0393-2249.18.03042-4

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guérin: experience of a single center

Rodolfo HURLE 1, Nicolò BUFFI 1, Giuliana LISTA 1, Pasquale CARDONE 1, Giovanni FORNI 1, Davide MAFFEI 1, Roberto PESCHECHERA 1, Silvia ZANDEGIACOMO 1, Luisa PASINI 1, Alessio BENETTI 1, Piergiuseppe COLOMBO 2, Massimo LAZZERI 1, Paolo CASALE 1, Giorgio GUAZZONI 1, Giovanni LUGHEZZANI 1

1 Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy; 2 Department of Pathology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy



BACKGROUND: To assess the outcomes of patients with high-grade (HG) pT1 bladder cancer (BC) treated with intravesical BCG therapy.
METHODS: The study population consisted of 185 patients with HG pT1 BC treated between 1998 and 2010. We aimed to determine recurrence-free (RFS) and progression-free survival (PFS), as well as the predictors of RFS and PFS.
RESULTS: Overall, 143 (77.3%) patients were males. Median age was 72 years (IQR: 66-78). Tumor size was ≥3 cm in 100 (54.1%) individuals. Most patients had single tumors (125; 67.6%). Primary, progressive and recurrent patterns of presentation were observed in 146 (78.9%), 21 (11.4%), and 18 (9.7%) cases, respectively. After 2nd-look TURB, 127 (68.6%) patients had no residual disease, 44 (23.8%) had Ta/CIS, and 14 (7.6%) had T1 HG BC. Twenty-two (11.9%) patients experience early recurrence after BCG. Of these, 12 patients (54.5%) were diagnosed with Ta/CIS, while 10 (45.5%) were diagnosed with HG pT1 BC. The median follow-up was 93 months (IQR: 63-147). Ten-year RFS and PFS rates were 69.6 and 79.2%. In multivariable Cox regression models, female gender (HR=2.41; P=0.001), progressive (HR=2.03; P=0.030) and recurrent (HR=3.87; P<0.001) pattern of presentation emerged as independent predictors of RFS, while age ≥70 years (HR=2.13; P=0.027), presence of multiple tumors (HR=2.06; P=0.019), and early recurrence (HR=3.88; P<0.001) emerged as independent predictors of PFS.
CONCLUSIONS: Intravesical BCG appears to be an effective treatment for HG pT1 BC. Caution should be used in patients aged ≥70 years, with multiple tumors or experiencing early recurrence.


KEY WORDS: Urinary bladder neoplasms - BCG vaccine - Treatment outcome

inizio pagina